

# **An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age**

Children's National Health System, Washington, District of Columbia, United States

New York University Langone Medical Center, New York, New York, United States

University of Utah Hospital, Salt Lake City, Utah, United States

Centro Hospitalar do Porto, Porto, , Portugal

Hospital Universitario Virgen Del Rocio, Sevilla, , Spain

UX003-CL203 is an open-label, multi-center, Phase 2 study to assess the safety and efficacy of UX003 in pediatric MPS 7 subjects.